News & Updates

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.